EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative Proteomics and Molecular Mechanisms of Non-Hodgkin Lymphoma Mice Treated with Incomptine A, Part II

Normand García-Hernández iD, Fernando Calzada iD, Elihú Bautista iD, José Manuel Sánchez-López iD, Miguel Valdes iD, Marta Elena Hernández-Caballero iD, Rosa María Ordoñez-Razo iD

Pharmaceuticals · 11.02.2025 · 18 (2) · 242

DOI: 10.3390/ph18020242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 11.02.2025. Verfasst von Normand García-Hernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Médica en Genética Humana, UMAE Hospital Pediatría 2° Piso, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro S…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Mexicano del Seguro Social, the Instituto Mexicano del Seguro Social.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Incomptine A (IA) has cytotoxic activity in non-Hodgkin lymphoma (NHL) cancer cell lines. Its effects on U-937 cells include induction of apoptosis, production of reactive oxygen species, and inhibition of glycolytic enzymes. We examined the altered protein levels present in the lymph nodes of an in vivo mouse model.

Methods

We induced an in vivo model with Balb/c mice with U-937 cells and treated it with IA or methotrexate, as well as healthy mice. We determined expressed proteins by TMT based on the LC-MS/MS method (Data are available via ProteomeXchange with identifier PXD060392) and a molecular docking study targeting 15 deregulated proteins. We developed analyses through the KEGG, Reactome, and Gene Ontology databases.

Results

A total of 2717 proteins from the axillary and inguinal lymph nodes were analyzed and compared with healthy mice. Of 412 differentially expressed proteins, 132 were overexpressed (FC ≥ 1.5) and 117 were underexpressed (FC ≤ 0.67). This altered expression was associated with 20 significantly enriched processes, including chromatin remodeling, transcription, translation, metabolic and energetic processes, oxidative phosphorylation, glycolysis/gluconeogenesis, cell proliferation, cytoskeletal organization, and with cell death with necroptosis.

Conclusions

We confirmed the previously observed dose-dependent effect of IA as a secondary metabolite with important potential as an anticancer agent for the treatment of NHL, showing that the type of drug or the anatomical location influences the response to treatment. The IA promises to be a likely safer and more effective treatment to improve outcomes, reduce toxicities, and improve survival in patients with NHL, initially targeting histones and transcription factors that will affect cell death proteins.

Schlagwörter

Stichwörter der Autor:innen

incomptine Amolecular dockingnecroptosisnon-Hodgkin lymphomaproteome TMT-based

Autor:innen und Institutionen

  • Unidad de Investigación Médica en Genética Humana, UMAE Hospital Pediatría 2° Piso, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, Mexico City 06725, Mexico.
  • Unidad de Investigación Médica en Farmacología, UMAE Hospital de Especialidades, 2° Piso CORSE, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, Mexico City 0672…
  • SECIHTI-División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica A.C., San Luis Potosí 78216, San Luis Potosí, Mexico.
  • Hospital Infantil de Tlaxcala, Investigación y Enseñanza, 20 de Noviembre S/M, San Matias Tepetomatitlan, Apetatitlan de de Antonio Carvajal 90606, Tlaxcala, Mexico.
  • Phagocytes Architecture and Dynamics, IPBS, UMR5089 CNRS-Université Toulouse 3, 205 route de Narbonne, 31077 Toulouse, France.
  • Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón S/N, Col. Casco de Santo Tomás, Miguel Hidalgo, Mexico City 11340, Me…

ORCID-Profile: Normand García-Hernández, Fernando Calzada, Elihú Bautista, José Manuel Sánchez-López, Miguel Valdes, Marta Elena Hernández-Caballero, Rosa María Ordoñez-Razo

Förderung

  • Instituto Mexicano del Seguro Social
  • the Instituto Mexicano del Seguro Social

Zitieren

APA

García-Hernández, N., Calzada, F., Bautista, E., Sánchez-López, J. M., Valdes, M., Hernández-Caballero, M. E., & Ordoñez-Razo, R. M. (2025). Quantitative Proteomics and Molecular Mechanisms of Non-Hodgkin Lymphoma Mice Treated with Incomptine A, Part II. Pharmaceuticals, 18(2), 242. https://doi.org/10.3390/ph18020242

Vancouver

García-Hernández N, Calzada F, Bautista E, Sánchez-López JM, Valdes M, Hernández-Caballero ME, et al. Quantitative Proteomics and Molecular Mechanisms of Non-Hodgkin Lymphoma Mice Treated with Incomptine A, Part II. Pharmaceuticals. 2025;18(2):242. doi:10.3390/ph18020242

BibTeX
@article{GarcaHernndez2025,
  author = {García-Hernández, Normand and Calzada, Fernando and Bautista, Elihú and Sánchez-López, José Manuel and Valdes, Miguel and Hernández-Caballero, Marta Elena and Ordoñez-Razo, Rosa María},
  title = {Quantitative Proteomics and Molecular Mechanisms of Non-Hodgkin Lymphoma Mice Treated with Incomptine A, Part II},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {2},
  pages = {242},
  doi = {10.3390/ph18020242}
}
Kostenlos starten →